Omega Therapeutics (NASDAQ:OMGA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Omega Therapeutics (NASDAQ:OMGAFree Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $12.00 target price on the stock. HC Wainwright also issued estimates for Omega Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.19) EPS.

OMGA has been the subject of a number of other research reports. Chardan Capital restated a buy rating and issued a $7.00 price target on shares of Omega Therapeutics in a research report on Tuesday, May 7th. Piper Sandler restated an overweight rating and set a $9.00 target price (down previously from $10.00) on shares of Omega Therapeutics in a research note on Wednesday, April 3rd. Finally, Wedbush reiterated an outperform rating and issued a $12.00 price target on shares of Omega Therapeutics in a research report on Monday, May 6th.

Get Our Latest Research Report on Omega Therapeutics

Omega Therapeutics Stock Performance

OMGA opened at $2.36 on Monday. Omega Therapeutics has a 12-month low of $1.30 and a 12-month high of $10.09. The company has a market cap of $129.88 million, a price-to-earnings ratio of -1.41 and a beta of 1.99. The company has a current ratio of 2.87, a quick ratio of 2.87 and a debt-to-equity ratio of 0.34. The company’s 50 day moving average is $3.03 and its 200 day moving average is $3.00.

Omega Therapeutics (NASDAQ:OMGAGet Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09. The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $0.93 million. Omega Therapeutics had a negative net margin of 1,868.35% and a negative return on equity of 136.04%. On average, equities research analysts predict that Omega Therapeutics will post -1.3 EPS for the current year.

Institutional Investors Weigh In On Omega Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. 683 Capital Management LLC boosted its position in shares of Omega Therapeutics by 7.0% during the third quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock worth $1,093,000 after acquiring an additional 33,242 shares during the last quarter. Murphy Pohlad Asset Management LLC purchased a new stake in Omega Therapeutics in the 4th quarter worth $50,000. Finally, Etfidea LLC bought a new position in shares of Omega Therapeutics during the 4th quarter valued at about $39,000. 97.47% of the stock is owned by hedge funds and other institutional investors.

Omega Therapeutics Company Profile

(Get Free Report)

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.

Featured Stories

Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with's FREE daily email newsletter.